{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:04:10Z","timestamp":1789884250007,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd005653","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000}}],"reference-count":149,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005653.pub2","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T11:55:49Z","timestamp":1276602949000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Pharmacological interventions for borderline personality disorder"],"prefix":"10.1002","author":[{"given":"Jutta","family":"Stoffers","sequence":"first","affiliation":[{"name":"& Department of Psychiatry and Psychotherapy; Department of Psychiatry and Psychotherapy, Freiburg; Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit A","family":"V\u00f6llm","sequence":"additional","affiliation":[{"name":"Institute of Mental Health; Section of Forensic Mental Health; University of Nottingham, Duncan Macmillan House Porchester Road Nottingham UK NG3 6AA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerta","family":"R\u00fccker","sequence":"additional","affiliation":[{"name":"Department of Medical Biometry and Statistics; German Cochrane Centre; University Medical Center Freiburg Stefan-Meier-Str. 26 Freiburg Germany 79104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Timmer","sequence":"additional","affiliation":[{"name":"Helmholtz Zentrum M\u00fcnchen Research Center for Health and Environment; Institute of Epidemiology; Ingolst\u00e4dter Landstrasse 1 M\u00fcnchen Germany 85764"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Huband","sequence":"additional","affiliation":[{"name":"Institute of Mental Health; Section of Forensic Mental Health; University of Nottingham, Duncan Macmillan House Porchester Road Nottingham UK NG3 6AA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Lieb","sequence":"additional","affiliation":[{"name":"University Medical Center Mainz; Department of Psychiatry and Psychotherapy; Untere Zahlbacherstr 8 Mainz Germany D-55131"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0002|cit2","unstructured":"Nurnberg HG Bogenschutz MP Atypical antipsychotic treatment of BPD: a 12-week, double-blind, placebo-control trial with olanzapine 156th annual meeting of the American Psychiatric Association San Francisco"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0924-977X(94)90296-8","article-title":"A trial of carbamazepine in borderline personality disorder","volume":"4","author":"Fuente","year":"1994","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"De la Fuente JM Lotstra F Carbamazepine in borderline personality disorder European Neuropsychopharmacology 1993 350","DOI":"10.1016\/0924-977X(93)90132-6"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4088\/JCP.v63n0511","article-title":"Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study","volume":"63","author":"Frankenburg","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo","volume":"43","author":"Goldberg","year":"1986","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1192\/bjp.bp.106.022707","article-title":"Omega-3 fatty acid supplementation in patients with recurrent self-harm","volume":"190","author":"Hallahan","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v62n0311","article-title":"A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder","volume":"62","author":"Hollander","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0009|cit9","first-page":"148","article-title":"Response of borderline patients to loxapine and chlorpromazine","volume":"43","author":"Leone","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0010|cit10","unstructured":"Linehan M Update on dialectical behavioral therapy for BPD 158th Annual Meeting of the American Psychiatric Association Atlanta, GA"},{"issue":"9","key":"10.1002\/14651858.CD005653.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4088\/JCP.v69n0617","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"69","author":"Linehan","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0012|cit12","first-page":"e1-e7 (pii: ej0","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"May 6th","author":"Linehan","year":"2008","journal-title":"published ahead of print: Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0014|cit13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0b013e318173a8fb","article-title":"Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up","volume":"3","author":"Loew","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0013|cit14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study","volume":"26","author":"Loew","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0165-0327(82)90026-X","article-title":"Pharmacological prevention of suicidal behaviour","volume":"4","author":"Montgomery","year":"1982","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0016|cit16","unstructured":"Montgomery SA Montgomery DB Janyanthi Rani S Roy DH Shaw PJ McAuley R Maintenance therapy in repeat suicidal behaviour: a placebo controlled trial Proceedings of the 10th international congress for suicide prevention and crisis intervention Ottawa 1979 227 9"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0017|cit17","first-page":"786","article-title":"Mianserin in the prophylaxis of suicidal behaviour: a double-blind placebo controlled trial","volume":"1981","author":"Montgomery","year":"1981","journal-title":"D\u00e9pression et Suicide"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0165-0327(82)90026-X","article-title":"Pharmacological prevention of suicidal behaviour","volume":"4","author":"Montgomery","year":"1982","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.1983.tb05864.x","article-title":"The prevention of recurrent suicidal acts","volume":"15","author":"Montgomery","year":"1983","journal-title":"British Journal of Clinical Pharamacology"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-007-0735-1","article-title":"Topiramate reduced aggression in female patients with borderline personality disorder","volume":"257","author":"Nickel","year":"2007","journal-title":"European Archives of Psychiatry & Clinical Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD005653.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4088\/JCP.v65n1112","article-title":"Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study","volume":"65","author":"Nickel","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eurpsy.2007.09.004","article-title":"Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up","volume":"23","author":"Nickel","year":"2008","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","article-title":"Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study","volume":"57","author":"Nickel","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/00048670701261251","article-title":"Topiramate treatment of aggression in male borderline patients","volume":"41","author":"Nickel","year":"2007","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00213-007-0740-0","article-title":"Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up","volume":"191","author":"Nickel","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study","volume":"163","author":"Nickel","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD005653.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.4088\/JCP.v68n1124f","article-title":"Aripiprazole treatment of patients with borderline personality disorder","volume":"68","author":"Nickel","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0028|cit28","unstructured":"Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Fondo de Investigaci\u00f3n Sanitaria (Ministry of Health Spain) Pfizer Ziprasidone in the treatment of borderline personality disorder www.clinicaltrials.gov"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.v69n0412","article-title":"Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study","volume":"69","author":"Pascual","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0030|cit30","unstructured":"McLean Hospital GlaxoSmithKline Study of lamotrigine treatment of affective instability in borderline personality disorder www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32832d6c2f","article-title":"A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder","volume":"e-pub ahead of","author":"Reich","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD005653.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","article-title":"SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder","volume":"159","author":"Rinne","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004714-199502000-00005","article-title":"Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder","volume":"15","author":"Salzmann","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0034|cit34","unstructured":"Eli Lilly Company Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized, flexible-dose, double-blind comparison with placebo www.lillytrials.com\/results_files\/zyprexa\/zyprexa_summary_6257"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0035|cit35","unstructured":"Eli Lilly Company Olanzapine in patients with borderline personality disorder www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0036|cit36","unstructured":"Eli Lilly Company Olanzapine in patients with borderline personality disorder www.who.int\/trialsearch"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0037|cit37","first-page":"S191","article-title":"Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study","volume":"9 (Suppl.1)","author":"Schulz","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study","volume":"193","author":"Schulz","year":"2008","journal-title":"The British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0039|cit39","unstructured":"Schulz SC Zanarini MC Detke HC Trzaskoma Q Lin D DeBerdt W Olanzapine for the treatment of borderline personality disorder: A flexible-dose, 12-week, randomized, double-blind, placebo-controlled study Proceedings of the Association of European Psychiatrsts 15th European Congress of Psychiatry, ; Madrid (Spain)"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Schulz SC Zanarini MC Detke HC Trzaskoma Q Lin D DeBerdt W Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study European Psychiatry 2007 S172","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Trzaskoma Q Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials Neuropsychopharmacology 2006 S229 30","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4088\/JCP.v65n0314","article-title":"Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder","volume":"65","author":"Simpson","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0043|cit43","unstructured":"Pascual JC Soler J Barrachina J Campins J Puigdemont D Alvarez E Olanzapine plus dialectical behavior therapy of patients with BPD Proceedings of the 157th annual meeting of the American Psychiatric Association"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder","volume":"162","author":"Soler","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1986.01800070081010","article-title":"Progress in pharmacotherapy of borderline disorders","volume":"43","author":"Soloff","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","article-title":"Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response","volume":"9","author":"Soloff","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder","volume":"50","author":"Soloff","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0269881107084004","article-title":"Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up","volume":"22","author":"Leiberich","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Tritt","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD005653.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study","volume":"62","author":"Zanarini","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.ajp.160.1.167","article-title":"Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"160","author":"Zanarini","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4088\/JCP.v65n0704","article-title":"A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder","volume":"65","author":"Zanarini","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0053|cit53","unstructured":"Eli Lilly Company Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized double-blind comparison with placebo www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0054|cit54","unstructured":"Eli Lilly Company Efficacy and safety of olanzapine in patients with borderline personality disorder www.who.int\/trialsearch\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0055|cit55","unstructured":"Eli Lilly Company Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized double-blind comparison with placebo www.lillytrials.com\/results_files\/zyprexa\/zyprexa_summary_6523\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Lin D A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo controlled study European Psychiatry 2007 S172 3","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0057|cit57","first-page":"S191","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study","volume":"9 (Suppl.1)","author":"Zanarini","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0058|cit58","unstructured":"Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Lin D A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study Proceedings of the Association of European Psychiatrists 15th European Congress of Psychiatry; Madrid (Spain)"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Trzaskoma Q Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials Neuropsychopharmacology 2006 S229 30","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"issue":"9","key":"10.1002\/14651858.CD005653.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4088\/JCP.v66n0904","article-title":"Oxcarbazepine in the treatment of borderline personality disorder: a pilot study","volume":"66","author":"Bellino","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.v67n0705","article-title":"Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study","volume":"67","author":"Bellino","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/070674370605100707","article-title":"Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy","volume":"51","author":"Bellino","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.v59n0302","article-title":"Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder","volume":"59","author":"Benedetti","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD005653.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v60n0906","article-title":"Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial","volume":"60","author":"Bohus","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4088\/JCP.v60n0710","article-title":"Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder","volume":"60","author":"Chengappa","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD005653.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects","volume":"54","author":"Coccaro","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0067|cit67","first-page":"151","article-title":"Fluoxetine trial in borderline personality disorder","volume":"26","author":"Cornelius","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0068|cit68","first-page":"333","article-title":"Haloperidol vs. phenelzine in continuation therapy of borderline disorder","volume":"29","author":"Cornelius","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD005653.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine","volume":"150","author":"Cornelius","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine","volume":"45","author":"Cowdry","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD005653.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0010-440X(93)90065-C","article-title":"Clozapine treatment of borderline patients: a preliminary study","volume":"34","author":"Frankenburg","year":"1993","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/15622970309167910","article-title":"Quetiapine in the treatment of borderline personality disorder","volume":"4","author":"Hilger","year":"2003","journal-title":"World Journal of Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.162.3.621","article-title":"Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder","volume":"162","author":"Hollander","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.npp.1300153","article-title":"Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0076|cit76","first-page":"75","article-title":"[Aggressiveness and personality disorders: Evaluation of efficacy and existence of predictors in the treatment with fluvoxamine and lithium] Aggressivit\u00e0 e disturbi della personalit\u00e0","volume":"44","author":"Malfa","year":"2003","journal-title":"Minerva Psychiatrica"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1521\/pedi.1990.4.2.173","article-title":"Lithium therapy for borderline patients: Preliminary findings","volume":"4","author":"Links","year":"1990","journal-title":"Journal of Personality Disorders"},{"issue":"8","key":"10.1002\/14651858.CD005653.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1176\/ajp.148.8.1064","article-title":"Fluoxetine in the treatment of borderline and schizotypal personality disorders","volume":"148","author":"Markovitz","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0079|cit79","first-page":"263","article-title":"Pharmacotherapy of impulsivity, aggression, and related disorders","volume-title":"Impulsivity and Aggression","author":"Markovitz","year":"1995"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0080|cit80","first-page":"773","article-title":"Venlafaxine in the treatment of borderline personality disorder","volume":"31","author":"Markovitz","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD005653.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0278-5846(89)90040-7","article-title":"Fluoxetine in borderline personality disorder","volume":"13","author":"Norden","year":"1989","journal-title":"Progress in Neuropsychopharmacology Biology & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0082|cit82","first-page":"524","article-title":"Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression","volume":"25","author":"Parsons","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-2004-827243","article-title":"Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder","volume":"37","author":"Philipsen","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1002\/14651858.CD005653.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.4088\/JCP.v65n1018","article-title":"Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder","volume":"65","author":"Philipsen","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4088\/JCP.v63n0311","article-title":"Treatment of borderline personality disorder with risperidone.[see comment]","volume":"63","author":"Rocca","year":"2002","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.v64n0510","article-title":"Chronic depression and comorbid personality disorders: Response to sertraline versus imipramine","volume":"64","author":"Russell","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD005653.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0006-3223(99)00128-6","article-title":"Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia","volume":"46","author":"Schulz","year":"1999","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD005653.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1176\/ajp.141.11.1455","article-title":"Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol","volume":"141","author":"Serban","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD005653.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1986.01800070081010","article-title":"Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo","volume":"43","author":"Soloff","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0090|cit90","first-page":"177","article-title":"Amitriptyline and haloperidol in unstable and schizotypal borderline disorders","volume":"22","author":"Soloff","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0091|cit91","first-page":"177","article-title":"Behavioral dyscontrol in borderline patients treated with amitriptyline","volume":"23","author":"Soloff","year":"1987","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD005653.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1176\/ajp.143.12.1603","article-title":"Paradoxical effects of amitriptyline on borderline patients","volume":"143","author":"Soloff","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/ajp.155.4.543","article-title":"Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression","volume":"155","author":"Verkes","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/JCP.0b013e31819a4bae","article-title":"Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder","volume":"29","author":"Ziegenhorn","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0095|cit95","unstructured":"AstraZeneca Netherlands Medical Director The effect of quetiapine on psychotic-like symptoms in borderline personality disordered patients: a randomised placebo-controlled trial www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0096|cit96","unstructured":"Bohus M Evaluation of the efficacy of the opioid antagonist naltrexone on the incidence and intensity of flashbacks and dissociative states in patients with borderline personality disorder www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0097|cit97","unstructured":"Casas M Efficacy of omega-3 fatty acids on borderline personality disorder: a randomised, double blind clinical trial www.clinical trials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0099|cit98","unstructured":"Goodman M Effects of Dialectical Behavioral Therapy and escitalopram on impulsive aggression, affective instability and cognitive processing in Borderline Personality Disorder www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0098|cit99","unstructured":"Goodman M New AS Koenigsberg HW Hazlett E Flory J Siever L Psychotherapy and combined treatment in BPD: possible effects 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0100|cit100","unstructured":"Malevani J Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study www.controlled-trials.com\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0101|cit101","unstructured":"Ralevski E Topiramate for treatment of patients with borderline personality disorder and alcohol dependence www.clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0102|cit102","unstructured":"Schulz SC A double-blind and placebo controlled assessment of Depakote ER in borderline personality disorder www.clinicaltrials.gov\/"},{"issue":"6","key":"10.1002\/14651858.CD005653.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0447.2004.00461.x","article-title":"Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum","volume":"110","author":"Akiskal","year":"2004","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0104|cit104","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0105|cit105","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0106|cit106","volume-title":"Diagnostic and statistical manual of mental disorders, 4th edition, text revision","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0107|cit107","volume-title":"Handbook of Psychiatric Measures","author":"Task force for the Handbook of Psychiatric Measures","year":"2000"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD005653.pub2-BIB0108|cit108","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder","volume":"158","author":"American Psychiatric Association","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Oldham JM Guideline Watch: Practice guideline for the treatment of patients with borderline personality disorder. Available online at http:\/\/www.psych.org\/psych_pract\/treatg\/pg\/prac_guide.cfm 2005","DOI":"10.1176\/foc.3.3.396"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1521\/pedi.17.1.45.24053","article-title":"Reliability and validity of the Borderline Personality Disorder Severity Index","volume":"17","author":"Arntz","year":"2003","journal-title":"Journal of Personality Disorders"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0111|cit111","article-title":"Pharmacological interventions for people with borderline personality disorder","author":"Binks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1521\/pedi.18.3.226.35445","article-title":"Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention","volume":"18","author":"Black","year":"2004","journal-title":"Journal of Personality Disorders"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pmh.41","article-title":"The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials","volume":"2","author":"Duggan","year":"2008","journal-title":"Personality and Mental Health"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0116|cit116","volume-title":"SCL-90-R. Symptom-Checkliste von L.R. Derogatis","author":"Franke","year":"2002"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.138.7.896","article-title":"The diagnostic interview for borderline patients","volume":"138","author":"Gunderson","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0118|cit118","first-page":"218","article-title":"ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338)","volume-title":"Psychopharmacology Research Branch, Division of Extramural Research Programs","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders","volume":"8","author":"Herpertz","year":"2007","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD005653.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Review of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.08r04526gre","article-title":"Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials","volume":"71","author":"Ingenhoven","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0123|cit123","volume-title":"Borderline conditions and primary narcissism","author":"Kernberg","year":"1975"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2006.09.019","article-title":"DSM-IV personality disorders in the National Comorbidity Survey Replication (NCS-R)","volume":"62","author":"Lenzenweger","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"9432","key":"10.1002\/14651858.CD005653.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)16770-6","article-title":"Borderline personality disorder","volume":"364","author":"Lieb","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1749-6632.1997.tb52367.x","article-title":"Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes","volume":"836","author":"Linehan","year":"1997","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0127|cit127","article-title":"Assessing and managing suicide risk","volume-title":"Essentials of personality disorders","author":"Links","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1034\/j.1600-0447.2000.102004256.x","article-title":"The Collaborative Longitudinal Personality Disorders Study: baseline Axis I\/II and II\/II diagnostic co-occurrence","volume":"102","author":"McGlashan","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"9193","key":"10.1002\/14651858.CD005653.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0130|cit130","unstructured":"National Collaborating Centre for Mental Health (Commissioned by the National Institute for Health and Clinical Excellence) Borderline Personality Disorder: treatment and management. National Clinical Practice Guideline Number 78 http:\/\/www.nice.org.uk\/nicemedia\/pdf\/Borderline%20personality%20disorder%20full%20guideline-published.pdf The British Psychological Society and The Royal College of Psychiatrists"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0131|cit131","unstructured":"National Institute for Health and Clinical Excellence http:\/\/www.nice.org.uk\/aboutnice\/whatwedo\/niceandthenhs\/UsingNICEGuidanceToCutCostsInTheDownturn.jsp"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.yic.0000224784.90911.66","article-title":"Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials","volume":"21","author":"Nos\u00e8","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00131746-200405000-00003","article-title":"Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder","volume":"10","author":"Oldham","year":"2004","journal-title":"Journal of Psychiatric Practice"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.comppsych.2006.10.001","article-title":"The interface between borderline personality disorder and bipolar spectrum disorders","volume":"48","author":"Paris","year":"2007","journal-title":"Comprehensive Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005653.pub2-BIB0135|cit135","first-page":"229","article-title":"The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes","volume":"35","author":"Perez","year":"2007","journal-title":"Actas Espa\u00f1olas de Psiquiatr\u00eda"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0136|cit136","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"2","key":"10.1002\/14651858.CD005653.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1176\/appi.ajp.159.2.276","article-title":"Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder","volume":"159","author":"Skodol","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0138|cit138","first-page":"195","article-title":"Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation","volume":"62","author":"Soloff","year":"1998","journal-title":"Bulletin of the Menninger Clinic"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1521\/pedi.16.3.201.22542","article-title":"Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder","volume":"16","author":"Soloff","year":"2002","journal-title":"Journal of Personality Disorder"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/21674086.1938.11925367","article-title":"Psychoanalytic investigation of and therapy in the borderline group of neuroses","volume":"7","author":"Stern","year":"1938","journal-title":"Psychoanalytic Quarterly"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1192\/bjp.162.3.299","article-title":"Long-term outcome in personality disorders","volume":"162","author":"Stone","year":"1993","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0142|cit142","first-page":"83","article-title":"Prevalence, sociodemographics, and functional impairment","volume-title":"Essentials of Personality Disorders","author":"Torgersen","year":"2009"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0143|cit143","volume-title":"The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research","author":"World Health Organisation","year":"1993"},{"issue":"3","key":"10.1002\/14651858.CD005653.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1521\/pedi.17.3.233.22147","article-title":"Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology","volume":"17","author":"Zanarini","year":"2003","journal-title":"Journal of Personality Disorders"},{"issue":"1","key":"10.1002\/14651858.CD005653.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4088\/JCP.v65n0105","article-title":"Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years","volume":"65","author":"Zanarini","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1176\/appi.ajp.161.11.2108","article-title":"Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission","volume":"161","author":"Zanarini","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD005653.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1521\/pedi.2005.19.5.505","article-title":"The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up","volume":"19","author":"Zanarini","year":"2005","journal-title":"Journal of Personality Disorders"},{"issue":"6","key":"10.1002\/14651858.CD005653.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1176\/ajp.2007.164.6.929","article-title":"The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study","volume":"164","author":"Zanarini","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005653.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials","volume":"196","author":"Lieb","year":"2010","journal-title":"British Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005653.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:52:34Z","timestamp":1628531554000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005653.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":149,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005653.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}